article Open access
Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients
- aMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA
- ✉Corresponding author
Antimicrobial Agents and ChemotherapyAmerican Society for Microbiology2019-09-30 11 citations73 references
Looking for the full paper…
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Pretomanid (PA-824) is a nitroimidazole in clinical testing for the treatment of tuberculosis. A population pharmacodynamic model for pretomanid was developed using a Bayesian analysis of efficacy data from two early bactericidal activity (EBA) studies, PA-824-CL-007 and PA-824-CL-010, conducted in Cape Town, South Africa.